TWI706954B - 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 - Google Patents

用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 Download PDF

Info

Publication number
TWI706954B
TWI706954B TW105114192A TW105114192A TWI706954B TW I706954 B TWI706954 B TW I706954B TW 105114192 A TW105114192 A TW 105114192A TW 105114192 A TW105114192 A TW 105114192A TW I706954 B TWI706954 B TW I706954B
Authority
TW
Taiwan
Prior art keywords
methyl
purin
compound
amino
chloro
Prior art date
Application number
TW105114192A
Other languages
English (en)
Chinese (zh)
Other versions
TW201716410A (zh
Inventor
梁春根
苗昆
王劍平
貟紅英
鄭秀芳
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI706954(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW201716410A publication Critical patent/TW201716410A/zh
Application granted granted Critical
Publication of TWI706954B publication Critical patent/TWI706954B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105114192A 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 TWI706954B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2015/078507 2015-05-08
CN2015078507 2015-05-08
CN2016078785 2016-04-08
WOPCT/CN2016/078785 2016-04-08

Publications (2)

Publication Number Publication Date
TW201716410A TW201716410A (zh) 2017-05-16
TWI706954B true TWI706954B (zh) 2020-10-11

Family

ID=55910966

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105114192A TWI706954B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物
TW109131169A TWI768467B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109131169A TWI768467B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX393198B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI706954B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
MX388408B (es) * 2016-09-13 2025-03-19 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
MA52412A (fr) * 2018-02-28 2021-06-02 Hoffmann La Roche Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN113660957B (zh) * 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
BR112022005137A2 (pt) 2019-09-20 2022-06-14 Syngenta Crop Protection Ag Derivados heterocíclicos com substituintes contendo enxofre e sulfoximina ativos em termos pesticidas
WO2021154664A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097103A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193282A (ja) * 1997-12-26 1999-07-21 Sumitomo Pharmaceut Co Ltd 複素環化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203519A (zh) * 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CN103497192B (zh) * 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
KR102025276B1 (ko) 2011-11-09 2019-09-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 퓨린 유도체
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193282A (ja) * 1997-12-26 1999-07-21 Sumitomo Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
AU2016260683A1 (en) 2017-10-12
KR20180003612A (ko) 2018-01-09
AR104528A1 (es) 2017-07-26
RS59435B1 (sr) 2019-11-29
AU2016260683B2 (en) 2020-10-29
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
SI3294740T1 (sl) 2019-12-31
US20170275286A1 (en) 2017-09-28
CR20170496A (es) 2017-12-05
IL280769A (en) 2021-04-29
MX376761B (es) 2025-03-07
EP3294740B1 (en) 2019-09-04
CL2017002745A1 (es) 2018-05-18
MX2020010949A (es) 2022-06-16
MY182353A (en) 2021-01-20
RU2017142577A (ru) 2019-06-10
PL3294740T3 (pl) 2020-03-31
MX393198B (es) 2025-03-19
JP6738352B2 (ja) 2020-08-12
EP3294740A1 (en) 2018-03-21
AU2020256348A1 (en) 2020-11-12
US20200109144A1 (en) 2020-04-09
AU2022204666A1 (en) 2022-07-21
CN107580596A (zh) 2018-01-12
ES2753777T3 (es) 2020-04-14
PH12017502009A1 (en) 2018-03-26
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
JP2018515509A (ja) 2018-06-14
TWI768467B (zh) 2022-06-21
RU2017142577A3 (enExample) 2019-10-31
IL280769B2 (en) 2023-07-01
SG10202108841YA (en) 2021-09-29
BR112017023959A2 (pt) 2018-07-17
IL254947A0 (en) 2017-12-31
DK3294740T3 (da) 2019-11-04
HUE045906T2 (hu) 2020-01-28
HK1247925A1 (zh) 2018-10-05
BR112017023959B1 (pt) 2023-05-02
CN107580596B (zh) 2020-07-14
KR102690131B1 (ko) 2024-07-31
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US10399983B2 (en) 2019-09-03
NZ775222A (en) 2024-09-27
CA2982704A1 (en) 2016-11-17
US20160326177A1 (en) 2016-11-10
US9708325B2 (en) 2017-07-18
AU2020256348B2 (en) 2022-06-16
LT3294740T (lt) 2019-11-25
US11242345B2 (en) 2022-02-08
CA2982704C (en) 2023-10-24
IL280769B1 (en) 2023-03-01
IL254947B (en) 2021-02-28
NZ735648A (en) 2023-06-30
TW201716410A (zh) 2017-05-16
PT3294740T (pt) 2019-10-29
UA120450C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
TWI706954B (zh) 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
CN109153682B (zh) 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
TWI598343B (zh) 非核苷反轉錄酶抑制劑
WO2012147890A1 (ja) 新規アゾール誘導体
CN115867541A (zh) 氨基嘧啶酮衍生物
JP2025532670A (ja) Pcsk9阻害剤及びその使用方法
TW201400464A (zh) 新穎嘧啶化合物及含有此之醫藥
CN114450277A (zh) 用于治疗和预防乙型肝炎病毒感染的经取代的嘧啶
CN116867782A (zh) 吡唑酰胺衍生物
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
HK40067638A (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
HK40002185A (en) Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
HK1235064B (en) Indole carboxamides compounds useful as kinase inhibitors
HK1235064A1 (en) Indole carboxamides compounds useful as kinase inhibitors
HK1192227A1 (zh) 噻唑并嘧啶化合物